Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Elias J JabbourKoiji SasakiNicholas James ShortFarhad RavandiXuelin HuangJoseph D KhouryRashmi Kanagal-ShamanaJeffrey JorgensenIssa F KhouriPartow KebriaeiNitin JainYesid AlvaradoTapan Mahendra KadiaShilpa PaulGuillermo Garcia ManeroBouthaina Shbib DabajaJan A BurgerCourtney D D DiNardoNaval G DaverGuillermo Montalban BravoMusa YilmazMaro OhanianAlessandra FerrajoliJovitta JacobMeagan RostykusRebecca GarrisSusan O'BrienHagop M KantarjianPublished in: Cancer (2021)
The combination of inotuzumab and low-intensity mini-hyper-CVD chemotherapy with or without blinatumomab shows sustained efficacy in patients with R/R ALL.